{
    "title": "110_hr3368",
    "content": "The Act may be cited as the \"Pulmonary Hypertension Research and Education Act of 2007\". The Congress finds that pulmonary hypertension is a serious and often fatal condition where the blood pressure in the lungs rises to dangerously high levels. The walls of the arteries that take blood from the heart to the lungs thicken and constrict, leading to heart enlargement and failure. Federal investment in pulmonary hypertension research must be expanded to find a cure or effective treatment. Collaboration among research centers should be increased to address the difficulty in diagnosing the disease, which is often confused with other heart and lung conditions. New diagnostic standards have improved diagnosis rates. Pulmonary hypertension is a challenging diagnosis often confused with other heart and lung conditions. New diagnostic standards have improved diagnosis rates. In advanced stages, patients have limited activity and may become completely bedridden. The National Heart, Lung, and Blood Institute established the first pulmonary hypertension patient registry in 1981, providing valuable insights into the disease. The cause of pulmonary hypertension is not fully understood, and there is still no cure. Research on pulmonary hypertension has been crucial in understanding the illness. Studies are investigating immunologic and genetic factors, agents causing narrowing of blood vessels, and factors leading to cell growth and scar tissue formation in vessel walls. Treatments for pulmonary hypertension are advancing with six FDA-approved medications and more in trials, although effectiveness varies among patients. The number of physicians treating pulmonary hypertension and patients receiving treatment has significantly increased over the past decade, leading to a growing need for medical professional education. Lung transplantation is often a last resort treatment for pulmonary hypertension, as current medications have varying effectiveness and significant negative side effects impacting patients' quality of life. In 2006, there were 3,000 physicians treating pulmonary hypertension and 30,000 patients receiving treatment. Despite the availability of oral therapies, managing pulmonary hypertension remains complex. A meeting hosted by the National Heart, Lung, and Blood Institute emphasized the importance of communication among researchers for advancements in treating this disease. The Public Health Service Act is amended to include a section on pulmonary hypertension research and training, emphasizing the need for advancements in treating the disease. The Director of the Institute will establish a Pulmonary Hypertension Clinical Research Network to conduct clinical trials and collaborate on new treatment approaches for pulmonary hypertension. The network will include 15 clinical centers, an institute project scientist, and a data and coordinating center. The Pulmonary Hypertension Clinical Research Network will consist of 15 clinical centers, an institute project scientist, a data and coordinating center, a data and safety monitoring board, a steering committee, and an independent protocol review committee. The steering committee will determine the specific clinical trials to be conducted under this section. The Pulmonary Hypertension Clinical Research Network includes a steering committee responsible for selecting clinical trials, developing protocols, and analyzing results. Clinical trials may involve combination therapies, new drug avenues, endothelial progenitor cells, and treatment effects predictive of long-term outcomes. The Pulmonary Hypertension Clinical Research Network's Institute manages the organization and support for clinical trials, including the use of endothelial progenitor cells for pulmonary hypertension and discovering treatment effects predictive of long-term outcomes. The Institute project scientist oversees subject recruitment, trial progress, conflict of interest disclosure, and adherence to Institute policies. The Institute manages clinical trials, ensures disclosure of conflicts of interest, and conducts fiscal management with a grants management specialist. The Director appoints the Chair of the steering committee, members of the protocol review committee, and the data safety monitoring board. Additionally, there is a Pulmonary Hypertension Preceptorship and Training Program. The Director appoints the Chair of the steering committee, members of the protocol review committee, and the data safety monitoring board. A Pulmonary Hypertension Preceptorship and Training Program is established to educate medical professionals by experienced specialists in clinical settings. The Pulmonary Hypertension Preceptorship and Training Program aims to educate medical professionals in clinical settings to effectively diagnose, treat, and manage pulmonary hypertension. The program will establish at least five regional training sites across the United States at recognized healthcare centers, hospitals, or medical practices. Each site will have a designated contact person, and the Director will specify requirements for the program. The Pulmonary Hypertension Preceptorship and Training Program will establish regional training sites at recognized healthcare centers, hospitals, or medical practices. Each site will have a designated contact person, and the Director will specify requirements for the program. The nonprofit entity awarded the grant will establish mechanisms for participant recruitment and program guidelines. Authorization of appropriations is provided for fiscal years 2009 through 2012. Increasing public awareness of pulmonary hypertension is the focus of Section 4. The Secretary of Health and Human Services will develop and share information on pulmonary hypertension, including basic information, prevalence, related diseases, early diagnosis importance, and treatment options. Information will be disseminated through a national non-profit entity, with authorized appropriations for fiscal years 2009 through 2012. The Secretary of Health and Human Services will disseminate information to health professionals on pulmonary hypertension. The Secretary of Health and Human Services will develop and disseminate information on pulmonary hypertension to health care providers, including warning signs, early diagnosis importance, diagnostic criteria, and FDA-approved therapies. This information will be shared through a national non-profit entity with expertise in pulmonary hypertension. Authorization of appropriations is provided for this purpose. The Secretary of Health and Human Services will disseminate information on pulmonary hypertension through a national non-profit entity with expertise in the field. Appropriations are authorized for fiscal years 2009 through 2012. The Comptroller General of the United States will conduct a study on Medicare and Medicaid coverage standards for individuals with pulmonary hypertension, including all FDA-approved therapies. The study will consider outpatient or home health care settings for service delivery. A report on the findings must be submitted to Congress within six months of the Act's enactment."
}